Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down – What’s Next?

Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) gapped down before the market opened on Thursday . The stock had previously closed at $546.88, but opened at $505.55. Madrigal Pharmaceuticals shares last traded at $454.0720, with a volume of 263,073 shares changing hands.

Key Stories Impacting Madrigal Pharmaceuticals

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Rezdiffra continues to drive strong revenue growth. Second-quarter revenue reached $364.25 million, up 71.2% year over year and above the $352.13 million analyst consensus, reflecting continued demand for the company’s MASH drug. Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
• Positive Sentiment: The quarterly loss was narrower than expected. Madrigal reported a loss of $1.99 per share, beating estimates ranging from $2.55 to $2.68 per share, although the loss was wider than the $1.90-per-share loss recorded a year earlier. Madrigal Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: Analyst support remains favorable. Wells Fargo assigned Madrigal an Overweight rating, providing a positive signal for the company’s outlook. Madrigal Earns Overweight Rating from Wells Fargo
• Neutral Sentiment: Madrigal’s earnings call and quarterly presentation highlighted Rezdiffra’s contribution to the business and the company’s ongoing development efforts, but investors are weighing the pace of the commercial launch against the stock’s elevated valuation. Madrigal Q2 2026 Earnings Call Transcript
• Negative Sentiment: Shares fell despite the earnings beat. Investors appear concerned that Rezdiffra’s commercial growth is moderating, making the strong year-over-year revenue increase less compelling and raising expectations for evidence of sustained prescribing and sales momentum. MDGL Stock Down Despite Q2 Beat

Wall Street Analyst Weigh In

MDGL has been the topic of a number of research reports. Piper Sandler restated an “overweight” rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, June 24th. Truist Financial lifted their price objective on Madrigal Pharmaceuticals from $640.00 to $709.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Wells Fargo & Company started coverage on Madrigal Pharmaceuticals in a research report on Monday. They set an “overweight” rating and a $685.00 target price on the stock. Bank of America lowered their target price on Madrigal Pharmaceuticals from $550.00 to $542.00 and set a “neutral” rating on the stock in a report on Thursday, June 11th. Finally, Evercore set a $649.00 price target on Madrigal Pharmaceuticals in a research report on Thursday, May 7th. Fourteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $688.20.

Madrigal Pharmaceuticals Trading Down 5.2%

The company has a market cap of $10.78 billion, a price-to-earnings ratio of -36.25 and a beta of -1.05. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.50 and a quick ratio of 3.16. The business’s 50-day simple moving average is $516.48 and its 200-day simple moving average is $499.05.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.99) EPS for the quarter, beating the consensus estimate of ($2.68) by $0.69. Madrigal Pharmaceuticals had a negative net margin of 25.32% and a negative return on equity of 55.04%. The business had revenue of $364.25 million for the quarter, compared to analyst estimates of $352.13 million. During the same period in the prior year, the business earned ($1.90) earnings per share. The company’s quarterly revenue was up 71.2% on a year-over-year basis. Research analysts predict that Madrigal Pharmaceuticals, Inc. will post -7.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Madrigal Pharmaceuticals news, Director Richard S. Levy sold 5,682 shares of the stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $515.44, for a total transaction of $2,928,730.08. Following the sale, the director owned 22,015 shares in the company, valued at approximately $11,347,411.60. This represents a 20.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Soergel sold 1,042 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $495.74, for a total value of $516,561.08. Following the transaction, the insider directly owned 10,033 shares of the company’s stock, valued at $4,973,759.42. The trade was a 9.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 7,568 shares of company stock worth $3,880,711. 17.60% of the stock is owned by insiders.

Institutional Trading of Madrigal Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Flagship Harbor Advisors LLC purchased a new stake in Madrigal Pharmaceuticals during the 4th quarter worth about $29,000. Kemnay Advisory Services Inc. purchased a new position in Madrigal Pharmaceuticals in the 4th quarter valued at about $39,000. Quarry LP purchased a new position in Madrigal Pharmaceuticals in the 3rd quarter valued at about $39,000. Johnson Financial Group Inc. purchased a new position in Madrigal Pharmaceuticals in the 3rd quarter valued at about $50,000. Finally, Accent Capital Management LLC boosted its stake in shares of Madrigal Pharmaceuticals by 64.9% during the 4th quarter. Accent Capital Management LLC now owns 94 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 37 shares during the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-? agonist in Phase 3 development for the treatment of NASH.